Print

FibroGen, Inc. Announces Phase 2A Results for Investigational Oral Anemia Therapy FG-4592 Will Be Presented at American Society of Nephrology Renal Week  
11/22/2010 10:25:04 AM

DENVER--(BUSINESS WIRE)--FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin. The results of the study will be presented by lead investigator Anatole Besarab, MD, of Henry Ford Hospital in Detroit, Michigan, in a free communication on Saturday November 20, 2010 at 5:30 in Korbel 4D (Abstract #SA-FC416).
//-->